

Combination transdermal non-opioid, non-narcotic treatment for pain utilizing SpeedGel Rx[®] and Astero[®]

■ **By Robert L. Wilbur, PharmD, CPh**

The treatment of pain is as complex as the origin of the pain itself. Though many studies and position papers highlight the need for a comprehensive, stepwise approach to pain management, too many prescribers have opted for opiates as the initial modality. This may be due to expediency, lack of sufficient time to fully assess the patient, or acquiescence to patient demands but it has fueled a growing epidemic.

Prescription opioid use for relief of noncancer pain has risen significantly in the last 15 years, contributing to a quadrupling of opioid overdoses and prescription opioid-related deaths. Data from the CDC document indicate that more than 70,000 people in the US died of drug overdose in 2017, of which 68% involved an opioid.¹

This crisis is resulting in heightened attention by health care professionals and organizations, law enforcement, and the government. Last year, the Centers for Disease Control and Prevention (CDC) released new opioid prescribing guidelines²; the Food and Drug Administration (FDA) added a black box warning for prescribing opioids and benzodiazepines³; US Surgeon General Vivek Murthy sent a letter to all US physicians asking them for commitment to “Turn the Tide” on the opioid crisis⁴; and the White House convened a summit of national leaders on this subject.

The general consensus is that clinicians must consider alternative therapies that will limit or decrease the utilization of opioids. However, acute and chronic pain are not identical in etiology, evaluation, and management, although overlap exists.⁵ The treatment of acute pain is mostly targeted and straight forward but the management of chronic pain is complex and at times controversial.⁶

The treatment of pain is meant to eliminate, modulate, or mute the pain signal and diminish the perception of pain in a patient. The approach to a patient’s pain must be individualized and multimodal. Depending on the pain severity, treatment must be tailored using multiple tools.

Two areas that lend themselves to effective non-opiate treatment are musculoskeletal and wound pain. Up until recently, the best available option was non-steroidal anti-inflammatory drugs (NSAIDs). Though often effective, they do bring with them the potential for serious adverse drug reactions (ADRs) and drug-drug interactions. These include but are not limited to allergic

reactions, bleeding, kidney failure and rarely liver failure. According to several studies, NSAIDs cause an increased risk of serious, even fatal, stomach and intestinal adverse reactions such as bleeding, ulcers and perforations. These events can occur at any time during treatment and without warning symptoms. Due to NSAIDs’ effects on clotting time, it is necessary to stop their use two weeks prior to surgery. In addition, the risk of myocardial infarctions and cerebral vascular hemorrhage in patients with a history of cardiovascular disease prompted the FDA to require a Black Box warning on NSAID products. SpeedGel Rx[®] is not associated with the NSAID class of drugs and can be used in combination with oral NSAID treatment without the risk of increasing the potential for NSAID ADRs unlike diclofenac gel which is an NSAID and can increase the risk of related ADRs. Newer, transdermal medications, such as Astero[®], SpeedGel Rx[®], and LiDORx[®], can bypass these concerns, treat the underlying condition and still deliver effective pain control.

Musculoskeletal (MSK) pain is most commonly a result of direct tissue trauma and/or overuse injury. These injuries involve a prolonged inflammatory response which produces a constellation of chemical mediators which increases the stimulation of nociceptors or lowers their activation threshold resulting in a prolonged sensation of pain. Treatment centers around reducing the inflammation, and the resulting mediators, at the site of injury during the healing process. Systemic NSAIDs typically require aggressive dosing at frequent intervals putting the patient at elevated risk of class associated ADRs. Ineffective dosing often results in the addition of an opiate to make the patient more comfortable. However, opiates have been shown not as effective for chronic MSK pain as once thought. A 2014 Cochrane Review found opioids unproven for the management of chronic low back pain.⁷

A clinically-proven safe and effective alternative is SpeedGel Rx[®], a proprietary blend of several natural ingredients at prescription strength. SpeedGel Rx[®] is a patented, topically applied transdermal gel that acts locally to reduce inflammation, bruising, and associated pain. A recent study by the Andrews Institute evaluated this product postoperatively on patients requiring ACL reconstruction surgery, measuring patient’s perception of pain and evaluating the use of opiates for pain control. Results show

■ Combination transdermal non-opioid, non-narcotic treatment for pain utilizing SpeedGel Rx® and Astero®

a 19% reduction of pain at Day 7 and 26% Day 21. Improvement in Range of Motion in comparison to placebo results are 12.8% at Day 14 and 7.2% Day 28. As a result of the patients' experience, there is a faster pain resolution with SpeedGel Rx® while they correspondingly demonstrated less need of narcotics.⁸ SpeedGel Rx® has also been shown to have positive effect on pain associated with bruising and time for bruise resolution,⁹ and specific SpeedGel Rx® constituents have been shown to shorten the process of acute inflammation as well as increasing tensile strength and collagen deposition in healing skin wounds.¹⁰

SpeedGel Rx® is effective in the management of pain associated with musculoskeletal injuries and is non-narcotic and has no neurocognitive effects, allows patients to return to normal activities of daily living including operating equipment and machinery and returning to work. By decreasing inflammation and associated pain, SpeedGel Rx® has been clinically proven to lessen the use of more high-risk medications, such as opiates.

By acting on inflammation and bruising, SpeedGel Rx® treats the underlying cause of the pain to heal the injury. However often times more pain relief in the form of an analgesic is required. There are many side effects, interactions and comorbidities associated with the use of NSAIDs. SpeedGel Rx® is safe to use in conjunction with Astero® on closed wounds, as a complimentary non-opioid, non-narcotic analgesic.

Astero® is a topically applied analgesic hydrogel indicated for closed and open wounds, vasculitis and burns and should be considered a first line treatment for these types of injuries. Closed and non-penetrating wounds are defined as: Soft tissue and bony injuries secondary to contusions, hematomas, crush injuries, and sprains/strains due to torsion, traction, compression and tearing, where the skin is intact.

Astero® is a FDA-cleared combination drug device of long proven hydrogel and the well know topical anesthetic Lidocaine in a 4% concentration. The anesthetic action of Astero® quickly quiets the damaged and hypersensitive sensory nerve endings and is specifically formulated to lessen the need for systemic pain medications including opiate based drugs.

Closed and open wounds have numerous, often interlinked, causes that may relate to the initial injury, the inflammatory response or infection. Pain can result from direct stimulation of peripheral pain receptors by inflammatory mediators, from tissue damage, and from the swelling that occurs as part of the inflammatory response.^{11,12}

In summary, pain management requires a comprehensive approach to the patient and the origin of the pain. By using a stepwise approach, beginning with

local therapy and medications at the site of injury, systemic ADRs (Adverse Drug Reactions) can be eliminated. In the event that systemic medications including opioids are needed, clinicians can reduce the amount of opiate usage and expedite weaning the patient off of opioid drugs. Newer drugs such as Astero® and SpeedGel Rx®, provide the clinician with effective first step and chronic treatment options for the most common presentations of pain and can be safely used together for closed wounds. Additionally, both SpeedGel Rx® and Astero® can safely be used in combination with an oral NSAID treatment without the risk of increasing the potential for NSAID ADRs.

References

1. Holly Hedegaard, M.D., Arialdi M. Miniño, M.P.H., and Margaret Warner, Ph.D. Drug Overdose Deaths in the United States, 1999–2017. NCHS Data Brief No. 329, November 2018
2. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. *MMWR Recomm Rep*. 2016 Mar 1;65(1):1–49
3. FDA drug safety communication. FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning [Internet] Washington, DC: US Food and Drug Administration; 2016. Aug 31
4. Turn the tide Rx. The Surgeon General's call to end the opioid crisis [Internet] Washington, DC: Surgeon General of the United States; 2016. Aug 31
5. Centers for Disease Control and Prevention. 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes — United States. *Surveillance Special Report 2*. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Published August 31, 2018
6. Overton HN, Hanna MN, Bruhn WE, Hutless S, Bicket MC, Makary MA; Opioids After Surgery Workgroup. Opioid-Prescribing Guidelines for Common Surgical Procedures: An Expert Panel Consensus. *J Am Coll Surg*. 2018 Oct;227(4):411–418. doi: 10.1016/j.jamcollsurg.2018.07.659. Epub 2018 Aug 14
7. Lowinson JH, Ruiz P, Millman RB, Langrod JG, editors. Lowinson and Ruiz's substance abuse: A comprehensive textbook. 4th ed. Baltimore, MD: Williams & Wilkins; 2005. pp. 863–904
8. Rosenblum A, Marsch LA, Joseph H, Portenoy RK. Opioids and the treatment of chronic pain: Controversies, current status, and future directions. *Exp Clin Psychopharmacol*. 2008 Oct;16(5):405–16
9. Petrenko AB, Yamakura T, Baba H, Shimoji K. The role of N-methyl-D-aspartate (NMDA) receptors in pain: a review. *Anesthesia & Analgesia*. 2003;97(4):1108
10. Loeser JD, Melzack R. Pain: an overview. *The Lancet*. 1999;353(9164):1607–1609
11. JM B. The neurobiology of pain. *The Lancet*. 1999;353(9164):1610–1615
12. Moffatt C., Franks P., Hollingworth H. Medical Education Partnership Ltd; London: 2004. "Understanding wound pain and trauma: An international perspective." EWMA position document. 2–7
13. Agrawal, Vaidehi; Wilson, Kirby; Reyna, Roxana; Emran, Mohammad Ali. Feasibility of 4% Topical Lidocaine for Pain Management During Negative Pressure Wound Therapy Dressing Changes in Pediatric Patients: A Case Study. *Journal of Wound, Ostomy & Continence Nursing*: November/December 2015 - Volume 42 - Issue 6 - p 640–642 10
14. MEP Ltd; London: 2004. "Minimizing pain at wound dressing-related procedures. A consensus document." World Union of Wound Healing Societies' Initiative
15. Cunningham, Michelle MD. Managing Pain Medication in the Outpatient Wound Clinic. *Today's Wound Clinic*, Volume 7 Issue 4 - May 2013
16. Ovington LG.: The well-dressed wound: an overview of dressing types. *Wounds* 1998; 10:1A
17. Chaparro LE, Furlan AD, Deshpande A, Mailis-Gagnon A, Atlas S, Turk DC. Opioids compared with placebo or other treatments for chronic low back pain: An update of the Cochrane Review. *Spine (Phila Pa 1976)* 2014 Apr 1;39(7):556–63
18. "Prospective Project to Determine the Efficacy of Prescribing SpeedGel Rx® in Decreasing Post-Operative Surgical Site Pain and Narcotic Use"; James R. Andrews M.D., Filippo Chillemi M.D., Mary Jane Robinson
19. Accelerated Resolution of Laser-Induced Bruising with SpeedGel Rx®: A Rater-Blinded Randomized Controlled Trial
20. GÁL P, TOPORCER T, GRENDÉL T, et al: Effect of Atropa belladonna L. on skin wound healing: biomechanical and histological study in rats and in vitro study in keratinocytes, 3T3 fibroblasts, and human umbilical vein endothelial cells. *Wound Repair Regen* 17: 378–386, 2009
21. Gensco Pharma, Data on file
22. An Exploratory, Single-blind Study to Evaluate Both the Onset of Anesthesia of LiDORx® in Patients Aged 18–88 Years - Patrick Hardigan, BS, MS, PhD, Nova Southeastern University, Director of Clinical Research